Skip to main content
. 2022 Aug 17;6:e2200107. doi: 10.1200/PO.22.00107

FIG 2.

FIG 2.

Relationship between BRAF class and tumor type in the context of MAPK-targeted therapy. (A) Response rates to MAPK-targeted therapy according to BRAF class and primary cancer type. P values calculated with Fisher's exact test. PFS according to BRAF class in the (B) entire cohort and for (C) melanoma and (D) lung primary tumors. P values calculated with log-rank test. MAPK, mitogen-activated protein kinase; PFS, progression-free survival.